In a patient with emphysema and severe tricuspid regurgitation plus moderate-to-severe mitral regurgitation, what is the appropriate management?

Management of Emphysema with Severe Tricuspid Regurgitation and Moderate-to-Severe Mitral Regurgitation

This patient requires combined surgical intervention on both the mitral and tricuspid valves if they are undergoing left-sided valve surgery, as severe TR should be addressed at the time of mitral valve intervention to prevent the high mortality associated with reoperation. 1

Initial Assessment and Risk Stratification

Critical Evaluation Points

Before proceeding with any intervention, you must assess:

• Right ventricular function: Severe RV dysfunction is a relative contraindication to surgery and predicts poor outcomes 2, 1
• Pulmonary pressures: Severe, irreversible pulmonary hypertension (particularly precapillary) indicates potential futility 1, 3
• Left ventricular function: Severe LV dysfunction affects surgical candidacy 3
• Emphysema severity: This complicates surgical risk and may elevate pulmonary pressures

The emphysema is particularly concerning as it may contribute to pulmonary hypertension and increase perioperative risk. You need right heart catheterization if noninvasive data are discordant or if there's uncertainty about the reversibility of pulmonary hypertension 1.

Surgical Approach (Preferred Strategy)

Class I Recommendations

Tricuspid valve surgery is mandatory when performing mitral valve surgery in the presence of severe TR 2, 1. The guidelines are unequivocal on this point—severe TR will not reliably improve after isolated mitral valve correction, and reoperation for TR carries 10-25% mortality 1.

Additional Tricuspid Repair Indications

Even if the TR were only moderate, you should still consider tricuspid repair if:

• Tricuspid annulus diameter ≥40 mm (or >21 mm/m² indexed) 2, 1
• Prior evidence of right heart failure 1

This is a Class IIa recommendation because moderate TR progresses in approximately 25% of patients post-mitral surgery, leading to reduced long-term survival 1.

Surgical Technique

• Tricuspid valve repair is strongly preferred over replacement 1
• Ring annuloplasty is the key technique, with prosthetic rings superior to suture annuloplasty (10% vs 20-35% residual TR at 5 years) 2
• If the valve is severely deformed or there's advanced tethering with RV dilatation, replacement with a large bioprosthesis should be considered 2
• Adding tricuspid repair does not significantly increase operative risk 2, 1

Medical Management (Bridging or Non-Surgical Candidates)

When Surgery is Not Feasible

If the patient has:

• Severe RV dysfunction
• Irreversible pulmonary hypertension from emphysema
• Prohibitive surgical risk

Then medical management becomes the primary strategy:

Loop diuretics (Class IIa) for systemic and hepatic congestion 1. However, be cautious—aggressive diuresis can worsen low-flow syndrome. Consider adding aldosterone antagonists, especially with hepatic congestion 1.

Pulmonary vasodilators (Class IIb) might be considered if there's reversible pulmonary hypertension demonstrated on invasive testing 1. This is particularly relevant given the emphysema.

Transcatheter Options (Emerging Alternative)

Recent Evidence

The 2025 ESC/EACTS guidelines upgraded transcatheter tricuspid valve interventions to Class IIa (Level of Evidence A) for symptomatic high-risk patients 4. However, this comes with critical caveats:

Contraindications to transcatheter approach:

• Severe LV dysfunction
• Severe RV dysfunction
• Precapillary pulmonary hypertension

These predict futility 3, 5.

Combined Transcatheter Approach

If surgical risk is prohibitive but the patient doesn't have the above contraindications, combined transcatheter edge-to-edge repair (TEER) of both mitral and tricuspid valves is emerging as an option 6, 7. However:

• This requires evaluation at an experienced Heart Valve Center 8, 9
• Procedural success for tricuspid TEER exceeds 95%, but outcomes depend heavily on RV function and pulmonary pressures 5
• Mean PA pressure >30 mmHg, transpulmonary gradient >17 mmHg, and RV-PA coupling ratio <0.406 predict poor outcomes 5

Clinical Decision Algorithm

Step 1: Assess surgical candidacy

• If acceptable surgical risk + preserved RV function + no irreversible pulmonary hypertension → Combined mitral and tricuspid surgery (Class I)

Step 2: If high surgical risk

• Evaluate for transcatheter options at a Heart Valve Center
• Perform right heart catheterization to assess pulmonary pressures and reversibility
• If severe RV dysfunction or precapillary PH → Medical management only
• If preserved RV function and acceptable hemodynamics → Consider combined TEER (Class IIa)

Step 3: If medical management only

• Loop diuretics titrated to symptoms
• Consider aldosterone antagonists
• Trial of pulmonary vasodilators if reversible component to PH
• Close monitoring for progression

Critical Pitfalls to Avoid

1. Do not defer tricuspid repair if proceeding with mitral surgery—reoperation mortality is unacceptably high 1

2. Do not assume TR will improve after isolated mitral correction—it won't in most cases with severe TR 1

3. Do not proceed with intervention if there's severe, irreversible RV dysfunction or pulmonary hypertension—outcomes will be futile 1, 3

4. Do not rely solely on echocardiography for pulmonary pressure assessment in emphysema patients—right heart catheterization provides more accurate data 1

5. Evaluate by a multidisciplinary Heart Team before any intervention—this is now a Class I recommendation for all severe valvular disease 10, 8, 9

The emphysema significantly complicates this case by potentially contributing to irreversible pulmonary hypertension, which would make any intervention futile. Careful hemodynamic assessment is essential before committing to a treatment strategy.